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Abstract 16 
Ionic excipients are commonly used in aqueous therapeutic monoclonal antibody (mAb) formulations. 17 
Novel excipients are of industrial interest, with a recent focus on Arg salt forms and their application 18 
as viscosity reducing and stabilizing additives. Here, we report that the calcium salt of dipicolinic acid 19 
(DPA, pyridine-2,6-dicarboxylic acid), uniquely present in nature in the core of certain bacterial 20 
spores, reduces the viscosity of a mAb formulated at 150 mg/mL, below that achieved by Arg 21 
hydrochloride at the same concentration (10 mM). DPA also reduced the reversible phase separation 22 
of the same formulation, which characteristically occurs for this mAb upon cooling to 4ᵒC. 23 
Differential scanning calorimetry and differential scanning fluorimetry did not reveal a conformation 24 
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destabilization of the mAb in the presence of 10 mM DPA, or by the related quinolinic acid (QA, 25 
pyridine-2,3-dicarboxylic acid). However, fluorescence spectrophotometry did reveal localized 26 
(aromatic) conformational changes to the mAb attributed to DPA, dependent on the salt form. While 27 
precise mechanisms of action remain to be identified, our preliminary data suggest that these DPA 28 
salts are worthy of further investigation as novel ionic excipient for biologics formulation. 29 
 30 
1. Introduction 31 
Bacterial cells of the orders Bacillales and Clostridiales initiate the process of sporulation upon 32 
sensing conditions of nutrient limitation. Sporulation is a tightly regulated cellular differentiation 33 
process that results in the formation of an endospore (hereafter spore), a metabolically dormant cell-34 
type that is adapted to resist physico-chemical and biological challenges for extended periods of time 35 
(Higgins and Dworkin, 2012; Tan and Ramamurthi, 2014). Whereas the primary protective feature of 36 
spores comprises an outermost proteinaceous coat that functions as a molecular barrier to chemical 37 
and enzymatic attack (McKenney et al., 2013), dormancy is achieved principally by two means. First, 38 
the cellular protoplast is surrounded by a thick layer of modified peptidoglycan, referred to as the 39 
cortex, which probably mechanically enforces the reduced water content of the spore core (Paredes-40 
Sabja et al., 2011). Second, the spore core environment is highly mineralised with calcium and other 41 
divalent metal ions, which are chelated with pyridine-2,6-dicarboxylic acid (dipicolinic acid or DPA). 42 
The latter is uniquely associated with bacterial spores in nature, comprising approximately 10-15 % of 43 
the dry weight of spores (Paredes-Sabja et al., 2011). While the precise function of DPA in spores has 44 
not definitively been elucidated, it clearly has a role in the maintenance of spore dormancy i.e. mutant 45 
strains of Bacillus that lack enzymes involved in DPA synthesis are unstable and lyse before maturity 46 
(Paredes-Sabja et al., 2011; Setlow, 2014). Similarly, the induced release of DPA from the spore core 47 
– whether achieved via nutrient induced germination, or by exposure of spores to certain cationic 48 
surfactants or extremely high pressures – results in the loss of spore dormancy and resistance 49 
properties (Setlow, 2014). 50 
One potential role for DPA at the molecular level is to promote the stability of essential spore-core 51 
located proteins during dormancy and spore germination, perhaps by minimising thermal-induced 52 
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motion and the likelihood of denaturation and aggregation. Given the apparent protective role of DPA 53 
in spores, we conjectured whether it would be able to fulfil a similar function as an excipient to 54 
pharmaceutical proteins of interest. The most commonly used pharmaceutical excipients include 55 
amino acids, polyols, salts, sugars, and surfactants (Manikwar et al., 2013). However, considerable 56 
effort has been made in recent years to identify and develop new excipients that mitigate the physical 57 
and chemical instability of biological drugs (Du and Klibanov, 2011; Lee et al., 2014). The use of 58 
novel Arg salts, for example, including equimolar formulations with glutamic acid, have been 59 
reported to exert synergistic effects in terms of reducing intermolecular attractions and aggregation, 60 
compared to Arg.HCl alone (Kheddo et al., 2016; Kheddo et al., 2014). 61 
Here we report on the use of DPA, and its quinolinic acid (QA) analogue, as novel excipients that 62 
may have potential in mAb formulation. This class of biopharmaceutical is of particular interest since 63 
subcutaneous injections of mAbs comprise low volume (<1.5 ml) high protein concentration (>100 64 
mg/ml) formulations. Such conditions promote aggregation, reversible self-association and particulate 65 
formation, with the resultant solubility and viscosity issues presenting considerable challenges to 66 
large-scale manufacture, product stability and delivery (Shire et al., 2004). 67 
 68 
2. Materials and Methods 69 
2.1 Chemicals and reagents 70 
All reagents were purchased at > 98% purity. 2,3-Pyridinedicarboxylic acid (quinolinic acid or QA), 71 
2,6-pyridinedicarboxylic acid (DPA), Bradford Reagent, calcium hydroxide, lysozyme and 72 
Scienceware® Aquet® liquid detergent were purchased from Sigma-Aldrich (Dorset, UK). Arg, Arg 73 
hydrochloride, histidine, histidine hydrochloride, and sodium chloride were acquired from J. T. Baker 74 
(Avantor Performance Materials B.V., Deventer, Netherlands). Calcium chloride dihydrate, SYPRO 75 
Orange protein gel stain 5000× in DMSO, and Tergazyme were obtained from Macron Chemicals 76 
(UK), Invitrogen (Paisley, UK) and Alconox (UK), respectively. MAb A is an IgG1 isotype with MW 77 
of 148.2 kDa, extinction coefficient or 1.443 cm2/mg and pI 9.30. MAb B is an IgG1 isotype with 78 
MW of 148.4 kDa, extinction coefficient of 1.58 cm2/mg and pI 7.5-7.8. MAb C is an IgG1 isotype 79 
with MW of 149.0 kDa, extinction coefficient of 1.55 cm2/mg and pI 9.04. MAbs A, B and C were 80 
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kindly provided by MedImmune Ltd., Cambridge, supplied at 50 mg/mL solution and stored at -80°C 81 
until use. 82 
 83 
2.2 Sample preparation 84 
MAb A was defrosted on the bench and gently swirled to mix; 45 mL at 50 mg/mL was then dialysed 85 
against 5 L of 25 mM His, 120 mM NaCl, pH 6 buffer for two days using dialysis cassettes (Thermo 86 
Scientific, Slide-A-Lyzer, 30 kDa MWCO). Dialysis buffer was changed after 3h and after 12h 87 
dialysis. After dialysis, the protein concentration was determined by absorbance at 280 nm using a 88 
NanoDrop instrument (Thermo Fisher Scientific Inc., Wilmington, USA). mAb A was then 89 
concentrated to 150 mg/mL using a Microsep Advance Centrifugal Device with a  30kD MWCO (Pall 90 
Corporation, NY, USA) in the absence or presence of different QA and DPA complexes. Before 91 
concentration, mAb A was diluted 1:2 using (1) 20 mM Ca(OH)2 20 mM QA; (2) 20 mM Ca(OH)2 20 92 
mM DPA; (3) 20 mM CaCl2.2H2O; (4) 40 mM Arg 20 mM QA; (5) 40 mM Arg 20 mM DPA; (6) 40 93 
mM Arg.HCl. Since both QA and DPA absorb ultra-violet light, the protein concentration was 94 
determined by Bradford assay. Briefly, protein samples were diluted 2000× in the same buffer they 95 
were prepared in and 50 µL of each sample added to a 96-well microplate. A calibration curve (0-0.25 96 
mg/mL) was prepared using mAb A in 25 mM His, 120 mM NaCl, pH6. 200 µL of Bradford reagent 97 
was added to each well before incubating with mild agitation at room temperature in the dark for 20 98 
min. Sample absorbance was read subsequently at 595 nm. 99 
 100 
2.3 Determination of mAb A thermal stability by differential scanning calorimetry (DSC) 101 
1 mg/mL mAb A samples were prepared in buffers containing various QA and DPA complexes at a 102 
range of concentrations. The following stock solutions used to prepare the samples: 50 mg/mL mAb 103 
A in 25 mM His, 120 mM NaCl, pH 6; 20 mM DPA (or QA) in 90 mM His, 120 mM NaCl, pH 6; 20 104 
mM Ca(OH)2, 20 mM DPA (or QA), 25 mM His, 120 mM NaCl, pH6; 40 mM Arg, 20 mM DPA (or 105 
QA), 25 mM His, 120 mM NaCl, pH6. Buffer strength had to be increased to 90 mM His instead of 106 
25 mM His in order to maintain a stable pH in the presence of 20 mM DPA or QA free acids. Samples 107 
were prepared using these stock solutions and then diluted in 25 mM His, 120 mM NaCl, pH 6 to 108 
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achieve the desired QA and DPA concentrations. Buffers and MilliQ water were degassed by 109 
sonication, whereas protein samples were degassed using a degassing station (TA Instruments). 110 
Lysozyme was used as a reference protein. 900 µL of each sample and buffer were pipetted into a 96-111 
deepwell plate and samples were heated from 25-90°C using a rate of 2°C/min and an equilibration 112 
time of 600 s using a NanoDSC differential scanning calorimeter (TA Instruments). Data analysis was 113 
performed in NanoAnalyze 3.6.0 software (TA Instruments). DSC curves were fitted using a two-state 114 
model of three independent domains to determine the melting temperature (Tm (ºC)) and enthalpy 115 
difference (∆H (KJ/mol) during thermal denaturation of each domain. The entropy difference (∆S 116 
(KJ/mol.K)) was determined using the following equation: ∆S = ∆H/(Tm+273.15) 117 
 118 
2.4 Determination of tertiary structure modifications by intrinsic fluorescence spectroscopy 119 
1 mg/mL mAb A in DPA (or QA), Ca2+-DPA (or QA), Arg-DPA (or QA) (2:1) with DPA or QA 120 
concentrations ranging from 0 -10 mM were prepared before adding 300 µL of each sample to  a 121 
black 96-well microplate (in sextuplicates). Fluorescence emission was monitored between 300-400 122 
nm using a Hitachi F-7000 fluorescence spectrophotometer.  Stock solutions and samples were 123 
prepared as in 2.3.  124 
 125 
2.5 Assessing the conformational stability of mAb A solutions by differential scanning 126 
fluorimetry (DSF) 127 
An intermediate protein stock solution was prepared by adding 2 µL SYPRO Orange (5000×) to 49 128 
µL of 50 mg/mL mAb A and 144 µL 25 mM His, 120 mM NaCl, pH 6 buffer to a final protein 129 
concentration of 12.5 mg/mL. The sample was vortexed and protected from light. The intermediate 130 
protein stock solution (2 µL) was pipetted to individual wells of a 96-well microplate along with 23 131 
µL of each buffer of interest (in triplicates). The buffers consisted of 25 mM His, 120 mM NaCl, pH 6 132 
with: 1 mM, 5 mM and 10 mM of DPA or QA; 10 mM Ca(OH)2, 10 mM DPA; 10 mM Ca(OH)2, 10 133 
mM QA; 10 mM CaCl2.2H2O; 20 mM Arg.HCl; 20 mM Arg, 10 mM DPA; 20 mM Arg, 20 mM QA.  134 
Thermal unfolding of mAb A then monitored using a Biorad CFX96 Real-Time PCR system using a 135 
temperature range of 20ºC to 95ºC with an increment of 0.2ºC.min-1 and a hold time of 10 s. As mAb 136 
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A unfolds, SYPRO Orange binds to its exposed hydrophobic surfaces, resulting in an increase of 137 
fluorescence. Two unfolding events most likely associated with unfolding of CH2 and CH3 domains 138 
of mAb A are observed at temperature of hydrophobicity 1 (Th1) and temperature of hydrophobicity 2 139 
(Th2), respectively. 140 
 141 
2.6 Cloud point assays 142 
mAb A at an initial concentration of 100 mg/mL was diluted 1:2 in the following buffers: 20 mM 143 
Ca(OH)2, 20 mM QA; 20 mM Ca(OH)2, 20 mM DPA; 20 mM CaCl2.2H2O; 40 mM Arg, 20 mM QA; 144 
40 mM Arg, 20 mM DPA; and 40 mM Arg.HCl. 800 µL of each sample was added to a quartz cuvette 145 
and the absorbance measured at 450 nm using a Cary 100 UV-Vis spectrophotometer equipped with a 146 
multicell Peltier and circulating water bath. As samples were cooled from 25°C to 4°C the absorbance 147 
was read incrementally at 0.5°C intervals. 148 
 149 
2.7 Viscosity measurements 150 
A 1 mL syringe was filled with mAb A at different concentrations (45, 75, 100 and 150 mg/mL) in 25 151 
mM His, 120 mM NaCl, pH 6 containing different excipients: 10 mM CaCl2.2H2O; 10 mM Ca(OH)2, 152 
10 mM QA, 10 mM Ca(OH)2, 10 mM DPA; 20 mM Arg.HCl; 20 mM Arg, 10 mM QA; and 20 mM 153 
Arg, 10 mM DPA. Sample viscosity was measured using an m-VROCTM viscometer (Rheosense, Inc., 154 
San Ramon, CA, USA). The chip was flushed with each sample for 10 s at a shear rate of 6000 s-1 and 155 
23°C, followed by a second injection for 30 s at a shear rate of 6000 s-1 at 23°C. The viscosity value 156 
measured during the second injection was considered to be more accurate. Between each sample 157 
measurement, the chip was flushed at a flow rate of 750 µL min-1 for 60 s in a sequential manner with 158 
the following solutions: 1% tergazyme, 1% aquet, filtered MilliQ water and sample buffer. 159 
 160 
2.8 Analysis of protein aggregation and fragmentation using High Performance Size Exclusion 161 
Chromatography (HPSEC) 162 
All samples were stored in 3 mL clear vials at 5 and 40 ºC. HPSEC analysis was performed on an 163 
Agilent HPLC system with a TSK-Gel G3000 column to assess monomer profile of the samples after 164 
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different time points: 0, 4 weeks (at 5 ºC and 40 ºC) and 12 weeks (at 5 ºC). The HPLC system was 165 
equipped with a multiple wavelength UV detector set at 280 nm wavelength. The samples were 166 
diluted to a concentration of 10 mg/mL using phosphate buffered saline (PBS) before loading into the 167 
column at an injection volume of 25 µL. The mobile phase used was 0.1 M sodium phosphate dibasic 168 
anhydrous 0.1 M sodium sulphate pH 6.8.  169 
 170 
3. Results 171 
3.1 Thermal stability of QA and DPA-containing formulations 172 
A DSC thermogram of mAb A is illustrated in Figure 1, revealing three visible unfolding events 173 
represented by three different peaks. The first peak refers to the unfolding of the CH2 domain at 67.9 174 
ºC, followed by a second peak associated with the unfolding of the CH3 domain at 77.0 ºC. Unfolding 175 
of the Fab fragment is represented by the peak at 84.0 ºC (Fukuda et al., 2014; Kameoka et al., 2007). 176 
Values of Tm, ∆H, and ∆S were determined for mAb A in the presence of QA and DPA, either alone 177 
or complexed with Ca2+ or Arg. Table 1 lists changes in these values (∆Tm, ∆∆H, and ∆∆S) compared 178 
to the values obtained for mAb A in 25 mM His 120 mM NaCl pH 6 without the addition of any 179 
organic acid. The differences on melting temperatures were negligible and never above 0.5 ºC. ∆∆S 180 
values followed the same trend in the presence of any of the organic acids even at low concentrations, 181 
with no significant variation on entropy associated with CH2 domain (∆∆S ≈ 0). CH3 and Fab 182 
domains presented positive ∆∆S values in the same order of magnitude and always larger for the Fab 183 
domain, which are associated with entropic gain of the mAb in the presence of the organic acid.  184 
 185 
Table 1 – Differences in Tm (∆Tm (ºC)), ∆H (∆∆H (KJ/mol)), and ∆S (∆∆S (KJ/mol.K) for mAb A in 186 
the presence of DPA or QA in different concentrations and complexed with either Ca2+ or Arg (2:1). 187 
 188 
Organic acid Domain ∆Tm (ºC) ∆∆H (KJ/mol) ∆∆S (KJ/mol.K) 
No Organic Acid CH2 - 
 
 
 
 
 
- - 
 
 
 
CH3 - - - 
Fab - - - 
1mM DPA CH2 -0.12 
-  
8.5 0.03 
 
CH3 -0.03 -16.7 1.15 
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Fab 0.12 -74.2 1.96 
5mM DPA CH2 -0.3 -52.5 -0.15 CH3 -0.3 -2.4 1.19 
Fab -0.21 15 2.21 
10mM DPA CH2 -0.53 -33.8 -0.10 CH3 -0.09 -3.9 1.19 
Fab 0.08 -149.3 1.75 
10mM Ca2+-DPA CH2 0.15 -43.3 -0.13 CH3 0.07 -17.3 1.15 
Fab 0.14 56 2.33 
20mM Arg 10mM DPA CH2 -0.1 -16.3 -0.05 CH3 0.12 4.1 1.21 
Fab 0.04 6 2.19 
1mM QA CH2 0.32 -33.2 -0.10 CH3 0.16 -14.4 1.15 
Fab 0.37 -104.3 1.88 
5mM QA CH2 0.07 13.1 0.04 CH3 0.12 -0.8 1.19 
Fab 0.15 97 2.44 
10mM QA CH2 0.02 -104.2 -0.31 CH3 0.19 -6.6 1.18 
Fab 0.04 44 2.29 
10mM Ca2+-QA CH2 0.31 -19.6 -0.06 CH3 0.28 -4.4 1.18 
Fab 0.35 -11 2.14 
20mM Arg 10mM QA CH2 0.43 -12.9 -0.04 CH3 0.41 -4.9 1.18 
Fab 0.32 126 2.52 
 189 
 190 
3.2 Assessment of local higher structure by intrinsic fluorescence spectrophotometry and DSF 191 
Fluorescence spectrophotometry methods may be used to assess conformational changes of 192 
polypeptides by exploiting the intrinsic fluorescence of aromatic amino acids (e.g. Trp). When a 193 
polypeptide unfolds or changes conformation, there is a change in the polarity of the 194 
microenvironment surrounding the aromatic amino acids, leading to a change in average emission 195 
fluorescence wavelength (e.g. 330 nm in a polypeptide where a Trp is fully buried to 350 nm where a 196 
Trp is fully exposed to the aqueous environment). In this study, the maximum emission wavelength 197 
was kept at 330 nm for the mAb in the presence of either DPA or QA acids or salts. However, a 198 
decrease in fluorescence intensity at 330nm was observed with increasing concentrations of the 199 
organic acids (DPA and QA) (Figure 2), indicating local changes in the polarity of the 200 
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microenvironment surrounding the aromatic amino acids. This decrease in fluorescence may be due to 201 
quenching, indicating a conformational change in the polypeptide upon increased exposure of 202 
aromatic amino acids to solvent. At room temperature in the presence of DPA, local changes to the 203 
aromatic environment were attenuated by the Ca2+ (Figure 2, filled black squares) but not the Arg 204 
(Figure 2, open black triangles) salt forms. The interaction between organic acids and either Ca2+ or 205 
Arg is different: Ca2+ acts as a chelating agent, forming a bidentate bond between the calcium cation 206 
and two carboxylic groups of the organic acid, whereas Arg forms an ionic interaction between its 207 
charged amino group and the negatively charged carboxylic groups of the organic acids. These 208 
differences could conceivably affect the quenching process. In contrast, fluorescence intensity of mAb 209 
A in the presence of Arg-QA (2:1) (Figure 2, grey open circles) is always slightly higher than in the 210 
presence of Ca-QA or QA, indicating that the mAb A was less exposed to the aqueous environment. 211 
Notably, these results are in accordance with DSC data presented in Table 1. The Fab fragment of 212 
mAb A is thermodynamically stabilized by enthalpic gain (∆∆H = 126 kJ/mol) plus entropic gain 213 
(∆∆S = 2.52 kJ/mol.K) in the presence of Arg-QA (2:1).  214 
Conformational stability of polypeptides can also be assessed using Real-Time PCR-type 215 
instrumentation with an appropriate fluorescent dye (e.g. SYPRO Orange). In such systems folded 216 
polypeptides do not bind to the fluorescent dye, producing low extrinsic fluorescence signals. As the 217 
polypeptide unfolds or changes conformation, the fluorescent dye binds to the exposed hydrophobic 218 
regions producing increased extrinsic fluorescence intensity. In the current work, no significant 219 
difference in the temperature of hydrophobicity of mAb A was observed in the presence of variable 220 
concentrations of either QA or DPA, or when in the salt form with either Ca2+ or Arg (Figure 3). 221 
Again, these results are consistent with the DSC results, indicating that mAb A remains folded in the 222 
presence of the organic acids. 223 
 224 
3.3 Reduction of opalescence by QA and DPA-containing formulations 225 
Opalescence is a phase transition which is observed when density fluctuations of fluids near the 226 
critical transition point result in scattering of light (Kamerzell et al., 2011; Salinas et al., 2010). This 227 
results in the solution developing a cloudy-white and translucent appearance. The degree of 228 
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opalescence can be influenced by temperature, ionic strength, protein concentration and/or addition of 229 
excipients (Kamerzell et al., 2011). In this work, opalescence was determined by measuring the 230 
absorbance of 50 mg/mL mAb A solutions at 450 nm in the presence of different excipients. This 231 
wavelength was selected due to the fact that the pyridine ring absorbs UV light; therefore, absorbance 232 
was measured in the visible light region. Even though we did not determine the critical opalescence 233 
concentration for the mAb used in this study, the protein concentration was kept at 50 mg/mL, since 234 
mAb solutions at higher concentrations (150 mg/mL) were completely clear. The absorbance of mAb 235 
A solutions was measured at different temperatures - ranging from 4ºC to 25ºC – in the presence of 236 
different excipients (Figure 4). At 4 ºC, mAb A in buffer presented the highest degree of opalescence, 237 
as adjudged by association with the highest absorbance value. Opalescence decreased in the following 238 
order: Ca2+-DPA > CaCl2.2H2O > Arg.HCl = Ca2+-QA > Arg-DPA (2:1) > Arg-QA (2:1). Essentially, 239 
all tested salts of DPA and QA attenuated temperature-induced opalescence of mAb A, with Arg salts 240 
of DPA and QA outperforming Arg.HCl. The same trends were observed with increasing 241 
temperatures, although the differences between excipients were less obvious at 25 ºC. 242 
 243 
3.4 QA and DPA as viscosity modulators 244 
The ability of DPA and QA to reduce the viscosity of mAb A liquid formulations was also 245 
investigated. mAb A at a concentration of 150 mg/mL in 25mM His 120mM NaCl pH 6 had a 246 
viscosity of 53.77 cP. However, mAb A at concentrations up to 150 mg/mL showed a marked 247 
decrease in viscosity when formulated with low concentrations of any of the excipients tested (Figure 248 
5), with the viscosity decreasing in the following order: Arg.HCl > CaCl2.2H2O > Ca2+-DPA > Ca2+-249 
QA = Arg-DPA (2:1) = Arg-QA (2:1). The viscosity of mAb A in the presence of Ca2+-QA, Arg-DPA 250 
(2:1) and Arg-QA (2:1) was reduced approximately 4.5 times when compared to mAb A in His saline 251 
buffer, and 2.5 times when compared to mAb A formulated with the same concentration of Arg.HCl 252 
(Figure 5). 253 
 254 
3.5 Time- and thermal-stability of DPA-containing formulations 255 
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To exploit the broader applicability of DPA as a pharmaceutical excipient, we have further 256 
investigated the stability of two additional mAbs (mAb B and mAb C) formulated with DPA. DPA 257 
concentrations were increased up to 100 mM (200 mM Arg – 100 mM DPA) to understand the effects 258 
of higher excipient concentration on protein stability. Arg salts were selected over Ca2+ salts due to 259 
the limited aqueous solubility of Ca-DPA. Arg.HCl was used as a positive control (at 200 mM). After 260 
4 weeks at 40°C, aggregation was significantly reduced for both mAbs B and C for formulations 261 
containing either Arg.HCl or Arg-DPA, while there was a slight increase in fragmentation.  At 5°C 262 
there was no increase in aggregation or fragmentation even after 12 weeks (Table 2).  263 
 264 
Table 2 – Percentage of monomer (%Mon), aggregates (%Agg) and fragmentation (%Frag) of mAb B 265 
and mAb C at 5°C and 40°C measured by HPSEC. Controls were molecules in their base buffer:  266 
mAb B in 50 mM sodium acetate pH 5.5 and mAb C in 20 mM sodium succinate pH 6.0, 267 
respectively. 268 
  T0 T4 weeks at 40 °C T12 weeks at 5 °C 
Sample Formulation %Mon %Agg %Frag %Mon %Agg %Frag %Mon %Agg %Frag 
mAb B Control 98.46 1.37 0.17 26.37 71.02 2.61 97.91 1.9 0.19 
Arg.HCl 98.71 1.13 0.16 91.58 4.55 3.87 98.75 1.05 0.2 
Arg-DPA 98.76 1.1 0.15 84.06 9.67 6.27 98.72 1.09 0.19 
mAb C Control 96.98 3.02 0 90.23 8.85 0.92 96.55 3.45 0 
Arg.HCl 97.1 2.9 0 91.22 3.85 4.82 96.38 3.62 0 
Arg-DPA 97.1 2.9 0 90.14 3.54 6.32 96.82 3.10 0.08 
 269 
 270 
4. Discussion 271 
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The stability of protein-based liquid formulations is of significant interest to the pharmaceutical 272 
industry, since the physical instability of biopharmaceuticals can undermine their safety and efficacy. 273 
This is particularly relevant at the high protein concentrations required typically for therapeutic 274 
administration, where non-specific aggregation is more likely to occur. As such, excipient molecules, 275 
such as Arg, are added to biopharmaceutical drugs in order to supress aggregation, minimise phase 276 
separation, reduce viscosity and increase the shelf life of the product. 277 
The underlying mechanisms associated with Arg-mediated suppression of aggregation have not been 278 
definitively established but may involve protein-liquid surface tension effects, preferential surface 279 
interactions, and/or binding of the Arg guanidinium group to indole groups associated with Trp 280 
residues (Tsumoto et al., 2004). The role of the anion in Arg salt excipients is also important in terms 281 
of conferring protein stability (Schneider et al., 2011; Zhang et al., 2016). However, the addition of 282 
Arg.HCl is not a universal solution for all formulations. The generation of NOx by Arg and related 283 
compounds may also confer physico-chemical destabilising effects on biopharmaceutical formulations 284 
(Kim et al., 2016). Thus, there is a clear rationale for the introduction of alternative excipients that are 285 
useful for attenuating high concentration mAb formulations. 286 
Inspired by the employment of Ca2+-DPA by bacterial spores to promote protein stability during 287 
dormancy, this work sought to examine whether DPA and the QA analogue could function as novel 288 
excipients in the formulation of a model mAb. Results from the work demonstrated that the viscosity 289 
of relatively high concentration mAb A solutions markedly decreased when formulated with low 290 
concentrations of Arg-QA (2:1), Arg-DPA (2:1) and Ca2+-QA. Moreover, these excipients performed 291 
considerably better than both Arg.HCl and CaCl2.2H2O. Observed decreases in viscosity were to 292 
values that are commensurate with fill-finish in manufacture and/or subcutaneous injection i.e. in the 293 
range of 15 cP and lower. However, calcium salts of DPA and QA are of limited aqueous solubility 294 
and it may be necessary to identify salt forms that facilitate mAb formulation studies at concentrations 295 
employed typically in current mAb formulations i.e. 50 to 150 mM. 296 
In terms of potential mechanisms of action, structural perturbation of mAb A - in the presence of DPA 297 
salts in particular - was confined to localised mobilisation of aromatic side chains, at least as adjudged 298 
from intrinsic fluorescence analyses. More general conformational changes involving gross changes 299 
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to the protein secondary structural elements or surface hydrophobicity were not detected using 300 
calorimetric or fluorescence reporter dye-based techniques. With this in mind - and since protein-301 
protein interactions involving reversible self-association may involve exposed hydrophobic aromatic 302 
residues (Geoghegan et al., 2016) - it seems reasonable to hypothesise that the attenuation of 303 
temperature-induced phase separation of mAb A by DPA salts is promoted by preferential interactions 304 
with accessible aromatic side chains. A similar mode of localised conformational destabilisation of 305 
mAbs induced by Arg has also been proposed (Thakkar et al., 2012), whereas structural changes to 306 
protein tertiary structure are thought to be associated with binding of Arg to aromatic Trp and Tyr side 307 
chains (Wen et al., 2015). Accordingly, local structural changes to mAb A observed in the presence of 308 
DPA are not an indication of incompatibility with protein formulation. Notably, mAb A formulations 309 
containing the Arg salt of QA were associated with the lowest viscosity and opalescence, but 310 
displayed enhanced intrinsic fluorescence intensity. This may be related to an increase in the stability 311 
of the IgG domains in the presence of Arg.QA, detected as a small enthalpic gain by DSC.  312 
 313 
 314 
5. Conclusion 315 
In conclusion, this work introduces a new class of organic acids – inspired by their association with 316 
bacterial spores - as novel excipients in the context of protein formulation. We suggest that future 317 
work, at least in the medium term, should aim to elucidate further the mode of action of DPA and QA 318 
salts on mAb stability, characterise further the effects on mAb stability, and identify salts that are 319 
suitable for scaling up during manufacture. 320 
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 383 
Figure Captions 384 
 385 
Figure 1 – DSC thermograms of mAb A solutions (1 mg/mL) under different buffer conditions: (a) 386 
25mM His 120mM NaCl pH 6 (solid grey line); 10mM DPA 57.5mM His 120mM NaCl pH 6 387 
(dashed line); 10mM Ca(OH)2 10mM DPA 25mM His 120mM NaCl pH 6 (dotted line); 20mM Arg 388 
10mM DPA 25mM His 120mM NaCl pH 6 (solid black line). (b) 25mM His 120mM NaCl pH 6 389 
(solid grey line); 10mM QA 57.5mM His 120mM NaCl pH 6 (dashed line); 10mM Ca(OH)2 10mM 390 
QA 25mM His 120mM NaCl pH 6 (dotted line); 20mM Arg 10mM QA 25mM His 120mM NaCl pH 391 
6 (solid black line). 392 
 393 
Figure 2 – Fluorescence Intensity of mAb A at 330 nm (1 mg/mL in 25mM His 120mM NaCl pH 6) 394 
with different concentrations of DPA (filled grey circles), Ca2+-DPA (filled black squares), Arg-DPA 395 
(2:1 molar ratio) (open black triangles), QA (stars), Ca2+-QA (filled black diamonds), and Arg-QA 396 
(2:1 molar ratio) (open grey circles) (N=6). 397 
 398 
Figure 3 – Temperature of hydrophobicity of mAb A in the presence of DPA, Ca2+-DPA, Arg-DPA 399 
(2:1 molar ratio), QA, Ca2+-QA, and Arg-QA (2:1 molar ratio) determined by DSF (N=3). 400 
 401 
Figure 4 – Absorbance at 450 nm of mAb A (50 mg/mL in 25mM His 120mM NaCl pH 6; filled 402 
circles) in the presence of 10mM CaCl2.2H2O (stars), 10mM Ca2+-DPA (diamonds), 10mM Ca2+-QA 403 
(down triangles), 20mM Arg.HCl (open circles), 20mM Arg 10mM DPA (open triangles), and 20mM 404 
Arg 10mM QA (open squares) at different temperatures. 405 
 406 
Figure 5 – Viscosity measurements using m-VROC (Rheosense, Inc.) of 150 mg/ml mAb A in 25mM 407 
His 120mM NaCl pH 6 (labelled ‘mAb A’) in the presence of the following excipients: 10mM 408 
CaCl2.2H2O (CaCl2), 10mM Ca2+-QA (Ca-QA), 10mM Ca2+-DPA (Ca-DPA), 20mM Arg.HCl 409 
(Arg.HCl), 20mM Arg 10mM QA (Arg-QA), and 20mM Arg 10mM DPA (Arg-DPA). 410 
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